Skip to main content
. Author manuscript; available in PMC: 2015 Nov 7.
Published in final edited form as: Nature. 2015 Apr 29;521(7550):94–98. doi: 10.1038/nature14395

Figure 2. B cells inhibit oxaliplatin-induced T cell activation.

Figure 2

a, CD8+ cells in TRAMP prostates (WT, Jh-/-; n=4-6/group) from mice treated as in 1a, enumerated by flow cytometry and normalized to CD45+ cells. b, Mice (n=6-8/group) bearing MC tumors were analyzed as above for CD8+ cells in spleens and tumors after 3 chemotherapy cycles. c, d, Q-RT-PCR analysis of Perforin and Ifnγ mRNA in MC tumors collected as in (b) (n=4-7). e, IFNγ expression by CD8+ cells from tumors (n=6-8) from (b) after in vitro re-stimulation with tumor cell lysate. f-h, Expression of GrzB and Ki-67 (f), PD-1and Tim-3 (g) and BTLA (h) in CD8+ T effector cells (CD8+CD44+; f,g) or total CD8+ cells (h) from tumors of MC inoculated mice (b). Results are percentages of positive cells in tumoral CD8+ cells or mean fluorescence intensities (MFI) and are means ± s.e.m of 3 independent experiments (n=6-8 mice/group). Mann-Whitney and t tests were used to determine significance shown as above.